The FDA granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
Read more: FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor